Skip to main content

Table 1 The baseline characteristics of the study participants enrolled during the therapeutic efficacy study in Uganda 2018–2019

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Characteristics, location

Treatment arm

AL (N = 305)

DP (N = 285)

Female sex n/N (%)

 Kwania district

59/104 (56.7)

54/95 (56.8)

 Busia district

63/102 (61.8)

48/94 (51.1)

 Arua district

48/99 (48.5)

56/96 (58.3)

Age in years, median (range)

 Kwania district

6.0 (1.0–10.0)

6.0 (1.0–10.0)

 Busia district

2.0 (0.5–10.0)

3.0 (0.5–10.0)

 Arua district

3.0 (0.5–10.0)

3.0 (0.8–10.0)

Temperature, °C, mean (SD)

 Kwania district

37.4 (1.3)

37.4 (1.2)

 Busia district

38.0 (0.9)

37.8 (0.9)

 Arua district

38.4 (1.0)

38.1 (1.0)

Parasite density/μl, Geometric mean, (95% CI)

 Kwania district

36,910 (29,193–46,666)

30,906 (24,067–39,687)

 Busia district

35,073 (28,235–43,567)

29,142 (22,643–37,506)

 Arua district

43,536 (34,973–54,194)

45,083 (35,329–57,530)

Hemoglobin level, g/dl, mean (SD)

 Kwania district

11.4 (1.4)

11.4 (1.5)

 Busia district

11.5 (1.7)

11.7 (1.9)

 Arua district

11.1 (1.7)

11.4 (1.6)

  1. AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; SD, standard deviation; CI, confidence interval